Promoting the development
Isofol Medical AB was founded in 2008 and was based on a research partnership between Professor Bengt Gustavsson and Merck & Cie, the world’s leading manufacturers of folate-based therapies. In 1978, the research team discovered that the folate-based treatment, leucovorin (LV), significantly increased the effect of the cytotoxic antimetabolite, fluorouracil (5-FU). This discovery subsequently led to the 5-FU/LV combination that now lies at the core of colorectal cancer treatment.
Professor Gustavsson formulated the hypothesis that the reason why only a few of his patients responded fully to the leucovorin treatment was due to their genetic ability to use enzymes to convert and metabolically activate the treatment. Although many judged it as impossible, Merck & Cie succeeded in 2005, after a long development process, finally producing a stable racemic mixture of the 1 and d forms of the non-active metabolite for leukovorin, MTHF. This new developed substance now forms the active ingredient in arfolitixorin.
A developmental programme in which the active component of arfolitixorin could be tested clinically was designed in order to confirm the original hypothesis. The programme was expensive and Isofol Medical AB was founded in order to finance the development work and enable any potential commercialisation. The original founders were Professor Gustavsson and Yield Life Science (publ.) AB, but the company has since grown, and by 2016, over 100 new shareholders had joined in the hope of realising the vision of improving the efficacy and minimising the side effects of treating cancer with antimetabolites.
The Phase III AGENT Study
Isofol has now initiated the pivotal phase III AGENT study in order to demonstrate the efficacy of arfolitixorin in the treatment of patients with colorectal cancer.